Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. reported a significant increase in its interim financial results for the first half of 2025, with a 15.9% rise in revenue and a 29.9% increase in profit compared to the previous year. The growth was primarily driven by sales of innovative drugs and licensing revenue, highlighting the company’s strong market position and strategic focus on R&D and innovation to meet clinical needs.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$80.57 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Hengrui Pharma is a leading global pharmaceutical company based in China, recognized for its innovative approach in the pharmaceutical industry. It has been consistently ranked among the global Top 50 pharmaceutical companies and is notable for its extensive self-developed drug pipelines. The company focuses on the R&D, manufacture, and sale of pharmaceutical products, with a strong emphasis on innovative drugs across multiple therapeutic areas, including oncology, metabolic and cardiovascular diseases, immunology, respiratory diseases, and neuroscience.
Average Trading Volume: 5,972,041
Current Market Cap: HK$457.1B
For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.